159 related articles for article (PubMed ID: 37130311)
1. Coronavirus Disease 2019, Diabetes, and Inflammation: A Systemic Review.
Ferguson M; Vel J; Phan V; Ali R; Mabe L; Cherner A; Doan T; Manakatt B; Jose M; Powell AR; McKinney K; Serag H; Sallam HS
Metab Syndr Relat Disord; 2023 May; 21(4):177-187. PubMed ID: 37130311
[TBL] [Abstract][Full Text] [Related]
2. Hypothesized mechanisms explaining poor prognosis in type 2 diabetes patients with COVID-19: a review.
Lisco G; De Tullio A; Giagulli VA; Guastamacchia E; De Pergola G; Triggiani V
Endocrine; 2020 Dec; 70(3):441-453. PubMed ID: 32779091
[TBL] [Abstract][Full Text] [Related]
3. Coronavirus Disease 2019 and Cardiometabolic Disease.
Kim CW; Aronow WS; Frishman WH
Cardiol Rev; 2022 May-Jun 01; 30(3):123-128. PubMed ID: 34224449
[TBL] [Abstract][Full Text] [Related]
4. Comorbidities in SARS-CoV-2 Patients: a Systematic Review and Meta-Analysis.
Ng WH; Tipih T; Makoah NA; Vermeulen JG; Goedhals D; Sempa JB; Burt FJ; Taylor A; Mahalingam S
mBio; 2021 Feb; 12(1):. PubMed ID: 33563817
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 and the role of chronic inflammation in patients with obesity.
Chiappetta S; Sharma AM; Bottino V; Stier C
Int J Obes (Lond); 2020 Aug; 44(8):1790-1792. PubMed ID: 32409680
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 in diabetic patients: Related risks and specifics of management.
Orioli L; Hermans MP; Thissen JP; Maiter D; Vandeleene B; Yombi JC
Ann Endocrinol (Paris); 2020 Jun; 81(2-3):101-109. PubMed ID: 32413342
[TBL] [Abstract][Full Text] [Related]
7. Predicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relating Obesity and Diabetes to COVID-19 Outcomes in Mexico.
Bello-Chavolla OY; Bahena-López JP; Antonio-Villa NE; Vargas-Vázquez A; González-Díaz A; Márquez-Salinas A; Fermín-Martínez CA; Naveja JJ; Aguilar-Salinas CA
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32474598
[TBL] [Abstract][Full Text] [Related]
8. Use of pioglitazone in people with type 2 diabetes mellitus with coronavirus disease 2019 (COVID-19): Boon or bane?
Jagat J M; Kalyan K G; Subir R
Diabetes Metab Syndr; 2020; 14(5):829-831. PubMed ID: 32540737
[TBL] [Abstract][Full Text] [Related]
9. Diabetes in the COVID-19 pandemic era.
Bonansea TCP; Santos LPD; Zintl K; Souza ACDS
Rev Assoc Med Bras (1992); 2021; 67Suppl 1(Suppl 1):157-162. PubMed ID: 34406303
[TBL] [Abstract][Full Text] [Related]
10. The Management of COVID-19-Related Coagulopathy: A Focus on the Challenges of Metabolic and Vascular Diseases.
Szilveszter M; Pál S; Simon-Szabó Z; Akácsos-Szász OZ; Moldován M; Réger B; Dénes L; Faust Z; Tilinca MC; Nemes-Nagy E
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628963
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Deranged Glucose Metabolism and Diabetes in the Pathogenesis and Prognosis of the Novel SARS-CoV-2: A Systematic Review of Literature.
Ukwenya VO; Adelakun SA; Fuwape TA; Adeagbo AS
Curr Diabetes Rev; 2022; 18(3):e060821195355. PubMed ID: 34365925
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 and its cardiovascular effects: a systematic review of prevalence studies.
Pellicori P; Doolub G; Wong CM; Lee KS; Mangion K; Ahmad M; Berry C; Squire I; Lambiase PD; Lyon A; McConnachie A; Taylor RS; Cleland JG
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013879. PubMed ID: 33704775
[TBL] [Abstract][Full Text] [Related]
13. Increasing adiposity and the presence of cardiometabolic morbidity is associated with increased Covid-19-related mortality: results from the UK Biobank.
Patel KHK; Li X; Quint JK; Ware JS; Peters NS; Ng FS
BMC Endocr Disord; 2021 Jul; 21(1):144. PubMed ID: 34217276
[TBL] [Abstract][Full Text] [Related]
14. Monocytopenia, monocyte morphological anomalies and hyperinflammation characterise severe COVID-19 in type 2 diabetes.
Alzaid F; Julla JB; Diedisheim M; Potier C; Potier L; Velho G; Gaborit B; Manivet P; Germain S; Vidal-Trecan T; Roussel R; Riveline JP; Dalmas E; Venteclef N; Gautier JF
EMBO Mol Med; 2020 Oct; 12(10):e13038. PubMed ID: 32816392
[TBL] [Abstract][Full Text] [Related]
15. Coronavirus Disease (COVID-19) Caused by (SARS-CoV-2) Infections: A Real Challenge for Human Gut Microbiota.
Vodnar DC; Mitrea L; Teleky BE; Szabo K; Călinoiu LF; Nemeş SA; Martău GA
Front Cell Infect Microbiol; 2020; 10():575559. PubMed ID: 33363049
[TBL] [Abstract][Full Text] [Related]
16. Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes.
Rajpal A; Rahimi L; Ismail-Beigi F
J Diabetes; 2020 Dec; 12(12):895-908. PubMed ID: 32671936
[TBL] [Abstract][Full Text] [Related]
17. Risk Factors for COVID-19: Diabetes, Hypertension, and Obesity.
Buscemi S; Corleo D; Randazzo C
Adv Exp Med Biol; 2021; 1353():115-129. PubMed ID: 35137371
[TBL] [Abstract][Full Text] [Related]
18. Obesity pandemic during COVID-19 outbreak: Narrative review and future considerations.
Cava E; Neri B; Carbonelli MG; Riso S; Carbone S
Clin Nutr; 2021 Apr; 40(4):1637-1643. PubMed ID: 33765600
[TBL] [Abstract][Full Text] [Related]
19. Impact of Metabolic Risk Factors on COVID-19 Clinical Outcomes: An Extensive Review.
Azevedo RB; Wandermurem DCR; Libório FCF; Machado MK; Ushijima NM; Narde RS; D Pecly IM; Muxfeldt ES
Curr Cardiol Rev; 2022; 18(6):e090522204452. PubMed ID: 35579126
[TBL] [Abstract][Full Text] [Related]
20. Implications of Low-grade Inflammation in SARS-CoV-2 Immunopathology.
Suárez-Reyes A; Villegas-Valverde CA
MEDICC Rev; 2021 Apr; 23(2):42. PubMed ID: 33974614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
